Specialty Pharmacy

Ongoing and active shortages are currently at the highest number since January 2001.

With gene therapy, anti-tissue factor pathway inhibitors, and RNA interference therapy targeting antithrombin, there are many new options that will be available for the patients impacted by hemophilia.

Pharmacists play a multifaceted role beyond dispensing medications, serving as educators, counselors, advocates, and pillars of emotional support for individuals and couples confronting infertility.

Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.

Christie Smith discusses navigating state pharmacy laws and advocating for policy changes to improve patient access and care coordination.

Elizabeth Cherry discusses the need to break down silos between manufacturers and health systems specialty pharmacies through more transparent collaboration to better serve patients.

Joe DePinto discusses innovative payment models like value-based agreements and warranties for cell and gene therapies

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

The COVID-19 pandemic spring boarded the evolution of pharmacies toward establishing their position as sites of care.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

Sarah Butler discusses the important role pharmacists play in educating patients on these changes in medication prices.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

Jon Mahrt discusses strategies for improving patient access to medications through affordability initiatives and utilization management of high-cost drugs.

Pharmacists can help patients distinguish between food allergies and intolerances, as well as facilitate access to life-saving medications and preventative care.

Christie Smith discusses a medically integrated dispensing model that aligns the goals of patients, physicians, and pharmacists.

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

At Asembia's AXS24 Summit, a clinician discusses the pathophysiology and classification of pulmonary arterial hypertension.

HSSPs improve medication adherence and reduce total health care costs by directly managing medications for complex chronic conditions like cancer, diabetes, COPD and CHF.

Speakers in a presentation discuss a specific patient with MS who experienced urinary complications and the methods used to treat her.

Tasmina Hydery, PharmD, BCGP, discusses how stakeholders can work together to generate and share real-world evidence on biosimilar effectiveness and switching in order to drive adoption and realize cost savings potential.

Pharmacists working with long-term care centers benefit from streamlined billing to support and build patient trust.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

With migraine as a leading disability for those under the age of 50, treatment options for migraine should be personalized to the patient and their needs.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Ocrelizumab (Ocrevus; Roche) is being investigated as a twice yearly 10-minute subcutaneous injection compared to the intravenous infusion formulation.

Adrijana Kekic, PharmD, a pharmacogenomics clinical specialist with Mayo Clinic in Phoenix, Arizona, discussed current guidelines for pharmacogenomics.